A Phase I Open-label, Fixed Sequence Study to Determine the Effect of Multiple Intravenous Doses of AZD6765 on the Pharmacokinetics of Oral Midazolam (CYP3A4 Substrate) in Healthy Subjects.
Phase of Trial: Phase I
Latest Information Update: 01 Oct 2017
At a glance
- Drugs Lanicemine (Primary) ; Midazolam
- Indications Major depressive disorder
- Focus Pharmacokinetics
- Sponsors AstraZeneca
- 27 May 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 22 Feb 2010 New trial record